Chester County News and Community Website
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) reported topline results from its Phase 3 RECONNECT study of ZYN002 in Fragile X syndrome (FXS), announcing that the trial …
Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New …
Harmony Biosciences to Present at Cantor Global Healthcare Conference Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) reported another quarter of double-digit revenue growth and solidified its position as a profitable, late-stage biotech leader, driven by continued momentum …
Harmony Biosciences Delivers Strong Q2 Growth, Advances Late-Stage Pipeline Read More PLYMOUTH MEETING, PA — Harmony Biosciences recently revealed compelling preclinical data for BP1.15205, a highly potent and selective orexin 2 receptor (OX2R) agonist, at the 39th Annual Meeting of the …
Harmony Biosciences Presents Promising Preclinical Data for Novel Narcolepsy Treatment Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) recently announced the resolution of its patent litigation against Lupin Limited regarding a generic version of WAKIX® (pitolisant hydrochloride). The …
Harmony Biosciences Reaches Settlement with Lupin Over WAKIX® Patent Litigation Read More PLYMOUTH MEETING, PA — Harmony Biosciences (Nasdaq: HRMY) announced its management team will join a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL, on …
Harmony Biosciences to Join Fireside Chat at Goldman Sachs Global Healthcare Conference Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) unveiled promising results from its Open-Label Extension (OLE) study evaluating ZYN002, a potential treatment for Fragile X syndrome (FXS). The …
Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced the addition of Ron Philip, President and CEO of Orbital Therapeutics, to its Board of Directors. Philip brings …
Harmony Biosciences Appoints Ron Philip to Board of Directors Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced that its management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference. …
Harmony Biosciences to Present at 24th Annual Needham Virtual Healthcare Conference Read More PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced the appointment of Adam Zaeske as its new Executive Vice President and Chief Commercial Officer (CCO), effective March 31, …
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer Read More